Press Releases

Date Title  
Toggle Summary BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 11, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has dosed its first patient with the Orbit Subretinal Delivery System (Orbit SDS) as
Toggle Summary BioTime Conducts Sale of Shares in OncoCyte Corporation
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 2, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, announced the pricing of the sale of 2,250,000 shares of common stock of OncoCyte Corporation at a price to
Toggle Summary BioTime Announces Appointment of General Counsel
ALAMEDA, Calif. --(BUSINESS WIRE)--May 22, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has appointed Chase C. Leavitt as BioTime’s General Counsel and Corporate Secretary.
Toggle Summary BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
ALAMEDA, Calif. --(BUSINESS WIRE)--May 10, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant for 2019 of up to 9 million Israeli New Shekels
Toggle Summary BioTime Reports First Quarter 2019 Financial Results and Provides Business Update
Positive OpRegen ® Data Presented at Association for Research in Vision and Ophthalmology Annual Meeting Announced Issuance of New Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury Entered Into Exclusive Collaboration with Orbit Biomedical Ltd. ALAMEDA, Calif.
Toggle Summary BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury
ALAMEDA, Calif. --(BUSINESS WIRE)--May 6, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet needs, announced today the issuance of a Notice of Allowance for a patent from the United States Patent and Trademark Office
Toggle Summary BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
ALAMEDA, Calif. --(BUSINESS WIRE)--May 3, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, today announced that it will report its first quarter 2019 financial and operating results on Thursday, May 9 th , 2019, following
Toggle Summary BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting
Treatment with OpRegen ® Continues to be Well Tolerated with Signs of Structural Improvement in the Retina Observed in Some Patients ALAMEDA, Calif. --(BUSINESS WIRE)--May 2, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular
Toggle Summary BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference
ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 26, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that Edward D. Wirth, III , M.D., Ph.D., Chief Medical Officer of BioTime , will present at the 26 th Annual
Toggle Summary BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 16, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen ® , a retinal
Toggle Summary BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Oppenheimer & Co.
Toggle Summary BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Completed Acquisition of Asterias Biotherapeutics, Inc. Completed Distribution of AgeX Therapeutics Shares to BioTime Shareholders Entered Into Exclusive Collaboration with Orbit Biomedical Ltd. ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 14, 2019-- BioTime, Inc.
Toggle Summary BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company
Company Will Advance Three Clinical Stage Product Candidates Addressing Significant Unmet Needs in Dry-AMD, Spinal Cord Injury, and Immuno-Oncology ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 11, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), today announced the closing of its previously reported
Toggle Summary BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 7, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its fourth quarter and full year 2018 financial and operating results on Thursday, March 14 th
Toggle Summary BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 4, 2019-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that Francois Binette , PhD, Senior Vice President and Global Head of Product Development at BioTime, Inc.
Toggle Summary BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
ALAMEDA, Calif. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen ® , a retinal pigment epithelium
Toggle Summary BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias
ALAMEDA, Calif. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which included information on AgeX Therapeutics, Inc. (AgeX) (NYSE American: AGE) and BioTime’s two
Toggle Summary BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer
ALAMEDA, Calif. , Jan. 30, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its affiliate company, OncoCyte Corporation ( OncoCyte ) (OCX) , a developer of novel, non-invasive tests for the
Toggle Summary BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD
ALAMEDA, Calif. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has entered into a research and option agreement with Orbit Biomedical Limited (“Orbit Biomedical”). 
Toggle Summary BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase
ALAMEDA, Calif. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the appointment of Brandi L. Roberts , M.B.A. as Chief Financial Officer and Senior Vice President, Finance, effective
Toggle Summary BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 2, 2019-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley , Chief Executive Officer of BioTime will be presenting at the 2019 Biotech Showcase Investor